Sugi Predict

Sugi Predict / Compounds / SCHEMBL18151586

SCHEMBL18151586

SCHEMBL18151586

N#CCOc1ccc(-c2ccc3nc4n(c3c2)C(c2ccccc2)CC4)cc1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 5/20 0.35
▸ USP30 Q70CQ3 2/20 0.34
▸ ADORA2A P29274 1/20 0.33
▸ CTSA P10619 1/20 0.33
▸ P2RX7 Q99572 2/20 0.32
▸ MAOA P21397 1/20 0.32
▸ MAOB P27338 1/20 0.32
▸ PDE6D O43924 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ RIPK1 Q13546 2/20 0.31
▸ ESR1 P03372 1/20 0.31
▸ ESR2 Q92731 1/20 0.31
▸ SPHK1 Q9NYA1 1/20 0.31
▸ CYP11B1 P15538 1/20 0.31
▸ CYP11B2 P19099 1/20 0.31
▸ AKT1 P31749 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29794973 0.92 PRMT5 (0.36) TNFUSP30CTSAMAOAMAOB
SCHEMBL18151377 0.92 PRMT5 (0.36) TNFUSP30CTSAMAOAMAOB
SCHEMBL18151584 0.85 PIK3CA (0.39) TNFUSP30RIPK1SPHK1AKT1
SCHEMBL18151436 0.81 MMP3 (0.40) TNFUSP30SPHK1
SCHEMBL18151489 0.77 ATM (0.41) TNF
SCHEMBL18151253 0.77 CYP11B1 (0.43) TNFRIPK1CYP11B1CYP11B2AKT1
SCHEMBL18150993 0.76 CYP11B1 (0.41) TNFUSP30RIPK1CYP11B1CYP11B2
SCHEMBL16814777 0.76 TNF (0.48) TNFP2RX7RIPK1
SCHEMBL16796836 0.76 TNF (0.48) TNFP2RX7RIPK1
SCHEMBL18151456 0.76 TNF (0.41) TNFUSP30P2RX7RIPK1SPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288939-A1 TRICYCLIC MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-07 — — EP claimed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US claimed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO claimed
US-20260131007-A1 Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins AVILAR THERAPEUTICS, INC. (US) 2026-05-14 — — US disclosed
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2026-03-26 — — US disclosed
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-08-28 — — US disclosed
EP-4493221-A2 TARGETED BIFUNCTIONAL DEGRADERS Yale University (US) 2025-01-22 — — EP disclosed
CN-119212727-A Targeted bifunctional degradants 耶鲁大学 2024-12-27 — — CN disclosed
WO-2024182772-A2 MANNOSE 6-PHOSPHATE RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-09-06 — — WO disclosed
WO-2024098039-A2 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
WO-2023178199-A2 TARGETED BIFUNCTIONAL DEGRADERS YALE UNIVERSITY (US) 2023-09-21 — — WO disclosed
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-06-28 — — US disclosed
EP-3288939-A1 TRICYCLIC MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-07 — — EP disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 — — US disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 — — US disclosed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS SMURF2, SMURF1, MDM2 TNF 5/4885USP30 87/4885ADORA2A 1343/4885
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B TNF 4166/4885USP30 2616/4885ADORA2A 1074/4885
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 TNF 1/4885USP30 3926/4885ADORA2A 517/4885
US-20260131007-A1 Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins IGF2R, M6PR, MSR1 TNF 4238/4885USP30 3059/4885ADORA2A 852/4885
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 TNF 1/4885USP30 3926/4885ADORA2A 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.